We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
PTC Therapeutics Inc | NASDAQ:PTCT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.66 | 17.01 | 45.00 | 0 | 14:02:45 |
Delaware
|
|
001-35969
|
|
04-3416587
|
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
100 Corporate Court
|
|
|
South Plainfield, NJ
|
|
07080
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
PTC Therapeutics, Inc.
|
||||
|
|
||||
Date: July 3, 2017
|
By:
|
/s/ Christine Utter
|
|
||
|
Name:
|
Christine Utter
|
|||
|
Title:
|
Principal Financial Officer
|
|||
|
|
|
|||
|
|
|
|
|
Exhibit No.
|
|
Description
|
||
2.1
|
|
Amendment to the Asset Purchase Agreement dated April 20, 2017 (1)
|
||
23.1
|
|
Consent of Deloitte & Touche LLP
|
||
99.1
|
|
Press Release, dated April 20, 2017, issued by PTC Therapeutics, Inc. (1)
|
||
99.2
|
|
Audited financial statements of the EMFLAZA Business as of and for the years ended December 31, 2016 and 2015 and the independent auditors’ report thereon
|
||
99.3
|
|
Unaudited financial statements of the EMFLAZA Business as of and for the three months ended March 31, 2017
|
||
99.4
|
|
Unaudited pro forma combined statements of operations the year ended December 31, 2016 and for the three months ended March 31, 2017 and unaudited pro forma combined balance sheet as of March 31, 2017
|
1 Year PTC Therapeutics Chart |
1 Month PTC Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions